| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Drug Monitoring, Opiates, with Confirmation, Urine
Test Code39380
CPT Codes
80307
Includes
If you require medMATCH for this order code, you must also order code 39158 - Prescribed Drugs, medMATCH®. If 39158 is ordered, all Drug Monitoring order codes will be treated as medMATCH.
If this test code is not ordered with 39158, all medMATCH result codes will be DNR’d.
.
Initial screen of the Opiates drug class. If screen is positive, a confirmation will be performed at an additional charge (CPT code(s): 80361; G0480).
Confirmation includes the following analytes: Codeine, Hydrocodone, Hydromorphone, Morphine, Norhydrocodone
If this test code is not ordered with 39158, all medMATCH result codes will be DNR’d.
.
Initial screen of the Opiates drug class. If screen is positive, a confirmation will be performed at an additional charge (CPT code(s): 80361; G0480).
Confirmation includes the following analytes: Codeine, Hydrocodone, Hydromorphone, Morphine, Norhydrocodone
Preferred Specimen
20 mL urine in a clinical drug test transport vial
Minimum Volume
7 mL
Other Acceptable Specimens
Urine collected in urine collection container
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Preserved samples
Methodology
Screen: Immunoassay (IA) • Confirmation: Mass Spectrometry (MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 6 days a week.
Clinical Significance
Opiates possess exceptional analgesic properties and have become the mainstay of pain management therapies. Being both psychologically and physically addictive, the monitoring of opiate use and abuse is a major component of any treatment program. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring of the opiates is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.
